Filtered By:
Specialty: Infectious Diseases
Infectious Disease: Coronavirus
This page shows you your search results in order of date.
Order by Relevance | Date
Total 35 results found since Jan 2013.
Monoclonal antibodies against MERS coronavirus show promise in phase 1 NIH-sponsored trial
(NIH/National Institute of Allergy and Infectious Diseases) A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes MERS found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical company Regeneron. The trial was sponsored by NIAID.
Source: EurekAlert! - Infectious and Emerging Diseases - February 23, 2021 Category: Infectious Diseases Source Type: news
Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis
The public health crisis caused by coronavirus disease 2019 (COVID-19) has led to unparalleled international scientific collaboration to find a safe and effective treatment, particularly for hospitalized patients. With close to 2 million deaths, treatments that can reduce mortality are needed urgently. Large multi-centre clinical trials are underway, led by groups such as the US National Institutes of Allergy and Infectious Diseases (Adaptive COVID-19 Treatment Trial), the University of Oxford's Nuffield Department of Population Health (RECOVERY trial) and the World Health Organization (WHO) and participating countries (SOLIDARITY trial).
Source: International Journal of Infectious Diseases - February 1, 2021 Category: Infectious Diseases Authors: Todd C. Lee, Emily G. McDonald, Guillaume Butler-Laporte, Luke B. Harrison, Matthew P. Cheng, James M. Brophy Source Type: research
NIH officials highlight COVID-19 vaccine facts, unknowns for healthcare providers
(NIH/National Institute of Allergy and Infectious Diseases) Healthcare providers must be able to explain the latest data supporting the safety and efficacy of vaccines for coronavirus disease 2019 (COVID-19) so they can strongly encourage vaccination when appropriate while acknowledging that uncertainty and unknowns remain. This message comes from a new commentary co-authored by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and other leading NIAID scientists in the journalAnnals of Internal Medicine.
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2021 Category: Infectious Diseases Source Type: news
Canadian Immunization Guide: "Anaphylaxis and other acute reactions following vaccination" chapter update
CONCLUSION: The updated CIG chapter provides healthcare providers with further clarity in recognizing and managing anaphylaxis in community settings. The updated intramuscular epinephrine dosage table will aid in optimal epinephrine administration, while the revised guidance against the use of diphenhydramine hydrochloride will prevent its unnecessary stockpiling in preparation for potential mass vaccination clinics related to the coronavirus disease 2019 pandemic.PMID:33447159 | PMC:PMC7799880 | DOI:10.14745/ccdr.v46i1112a04
Source: Can Commun Dis Rep - January 15, 2021 Category: Infectious Diseases Authors: Natalie Dayneka Christina Jensen Kyla Hildebrand Source Type: research
Peer-reviewed report on Moderna COVID-19 vaccine publishes
(NIH/National Institute of Allergy and Infectious Diseases) The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in theNew England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD).
Source: EurekAlert! - Infectious and Emerging Diseases - December 30, 2020 Category: Infectious Diseases Source Type: news
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
(NIH/National Institute of Allergy and Infectious Diseases) The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. NIAID and BARDA are funding the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - December 28, 2020 Category: Infectious Diseases Source Type: news
